Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex
References (11)
Prospects for new vaccines against tuberculosis
Trends Microbiol.
(1995)- et al.
Purification, characterization and identification of a 32 kD protein antigen of Mycobacterium bovis BCG
Microbiol. Pathogen.
(1987) - et al.
Expression and immunogenicity of M. tuberculosis antigen 85 by DNA vaccination
Vaccine
(1997) - et al.
Global burden of tuberculosis
- et al.
The BCG experience: implications for future vaccines against tuberculosis
There are more references available in the full text version of this article.
Cited by (148)
Recent progress in the design of DNA vaccines against tuberculosis
2020, Drug Discovery TodayImmunogenicity of late stage specific peptide antigens of Mycobacterium tuberculosis
2019, Infection, Genetics and EvolutionIn vivo electroporation of a codon-optimized BER <sup>opt</sup> DNA vaccine protects mice from pathogenic Mycobacterium tuberculosis aerosol challenge
2018, TuberculosisCitation Excerpt :A synthetic scrambled antigen vaccine, comprised of overlapping, recombined peptides from four Ag85B, ESAT-6, PstS3 and Mpt83, is immunogenic and protective against experimental TB by stimulating stimulated CD4+ and CD8+ T cells [44]. In the context of DNA vaccination, Ag85A, Ag85B and ESAT-6 genes were the earliest and most successful attempts, in which several studies have already demonstrated promising protection in animal models [32,33,45,46]. An ESAT6-Ag85B fusion DNA vaccine elicited a similar level of protection as the BCG immunization, with similar lung pathology and bacterial burdens detected 28 days after an aerogenic challenge [47].
Copyright © 1997 Published by Elsevier Ltd.